News
Phase 3 trial compares a new albumin-bound paclitaxel with the standard form in advanced breast cancer
AI-assisted summary Written by WellCareChina with AI assistance and checked against the original article.
A multicentre, double-blind phase 3 trial published in Cancer Communications on 26 June 2026 compared SYHX2011, a new albumin-bound paclitaxel formulation, with an existing albumin-bound paclitaxel in 459 patients with locally advanced or metastatic breast cancer across 56 centres in China. The confirmed objective response rate was 35.8% with SYHX2011 and 25.8% with the comparator (rate ratio 1.38, 95% CI 1.04-1.84); the trial was designed to show non-inferiority and the authors report that superiority was then confirmed. Rash was less frequent with SYHX2011 (16.2% versus 42.6% across all cycles), while grade 3 or higher treatment-related adverse events were reported in 48.7% and 43.9% of patients respectively (NCT05753865).
Read the original article Opens the original source in a new tab.
Copyright and re-use
The original article is the authoritative text. This page carries our own summary and a link back; no part of the original is reproduced here.
Source tier A — open-access article; the link goes to the PubMed record because the publisher site blocks automated access (dev-083). Our own summary, no full-text copy.